Generics are becoming an increasingly lucrative market with good prospects for the future. However, a report by US market data provider BCC Research shows that this is also a bit of an exclusive club. The top four global generics manufacturers in 2009 – Teva, Sandoz, Mylan and Watson – accounted for 40% of the world market.
Teva increases its global position with acquisition of Ratiopharm
Home/Pharma News
|
Posted 10/09/2010
0
Post your comment
Teva, with an 18% market share in 2009, is reinforcing its global number one position with the recent acquisition of the 5th largest generic manufacturer, Ratiopharm. This move has increased both its global position and has propelled it to the number one position in Europe.
Teva's President and CEO, Mr Shlomo Yanai, commented that “increasing Teva's market share in Europe – a geography with tremendous potential for generics penetration – is an important pillar of our long-term growth strategy. With the acquisition of Ratiopharm we will become the leader in key European markets and we are well-positioned to become the leader in many other European markets in the near future".
Related article
Teva with ratiopharm market leader in European generics
References
BCC Research. Generic Drugs: The Global Market. Report Code: PHM009E, Published: July 2009
Teva Press Release. Teva Completes Acquisition of ratiopharm. 10 August 2010
Guidelines
New guidance for biologicals in Pakistan and Hong Kong’s independent drug regulatory authority
Canada poised to remove requirement for Phase III trials for biosimilars
Policies & Legislation
Argentina streamlines drug approval process
ANVISA tackles 24-month backlog in biologicals post-registration petitions
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Formycon signs new aflibercept biosimilar pacts and launches ranivisio in Europe
Bio-Thera and Stada expand biosimilars alliance to include tocilizumab
Global partnerships for biosimilar commercialization announced
New denosumab and ustekinumab biosimilar launches in US, Canada and Japan
Related content
Formycon signs new aflibercept biosimilar pacts and launches ranivisio in Europe
Home/Pharma News Posted 13/11/2025
Bio-Thera and Stada expand biosimilars alliance to include tocilizumab
Home/Pharma News Posted 20/10/2025
New denosumab and ustekinumab biosimilar launches in US, Canada and Japan
Home/Pharma News Posted 10/07/2025
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment